Genital Tuberculosis in the Molecular Era Conventional Diagnosis, Molecular Testing, Specimen Selection and Emerging Genomic Technologies: A Critical Review
Journal of Infectious Diseases & Travel Medicine · 04.09.2026 · 10 (2) · 1-16
DOI: 10.23880/jidtm-16000206 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Infectious Diseases & Travel Medicine, online erschienen am 04.09.2026. Verfasst von Murugan Nandagopal und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Genital tuberculosis (GTB), particularly female genital tuberculosis (FGTB), is an important form of extrapulmonary tuberculosis and an under-recognized cause of infertility and reproductive morbidity in tuberculosis-endemic settings. Diagnosis is difficult because disease is frequently paucibacillary, may be focal or clinically silent, and often requires invasive sampling. Conventional methods including acid-fast bacilli microscopy, mycobacterial culture, histopathology, imaging and endoscopy provide complementary information but have important sensitivity, turnaround-time and interpretation limitations. Molecular diagnostics have expanded the diagnostic toolbox, but reported performance varies markedly according to specimen type, molecular target, assay architecture and reference standard.
Objective
To critically review conventional and molecular diagnostic approaches for genital tuberculosis, with particular emphasis on infertility-associated disease, specimen selection, molecular target selection, rapid nucleic acid amplification tests (NAATs), drug-resistance detection, emerging sequencing technologies and the methodological problem of imperfect reference standards.
Methods
A structured literature search was undertaken using PubMed/MEDLINE and targeted searches of WHO resources and major journal databases, with literature considered from database inception through 12 August 2026. Search concepts included genital/genitourinary tuberculosis, infertility, diagnosis, PCR, qPCR, GeneXpert, Xpert Ultra, Truenat, LAMP, sequencing and next-generation sequencing. Priority was given to primary diagnostic studies, systematic reviews/meta-analyses, major reviews and WHO guidance. Because this manuscript is a critical narrative review rather than a registered systematic review, no pooled de novo meta-analysis was performed. Diagnostic accuracy estimates were therefore interpreted in relation to specimen, population and reference-standard methodology.
Results
The evidence consistently indicates that no single test reliably excludes GTB across all clinical phenotypes. AFB microscopy and culture are highly specific when positive but often insensitive in paucibacillary disease. Histopathology can provide strong supportive evidence but may be negative when disease is focal or granulomatous inflammation is absent. PCR-based methods generally improve analytical detection, although target selection and reference-standard definitions strongly influence reported performance. Xpert MTB/RIF and Xpert Ultra offer rapid standardized testing and rifampicin-resistance information, but genital-TB-specific evidence remains much smaller than the broader extrapulmonary TB evidence base. Menstrual blood is a promising less-invasive specimen, but the evidence is heterogeneous. Targeted next-generation sequencing is increasingly relevant for resistance profiling after TB confirmation, although WHO recommendations currently focus on bacteriologically confirmed pulmonary TB and evidence for direct genital-TB diagnosis is limited. WHO's March 2026 update introduced near-point-of-care NAATs, tongue-swab sampling and sputum pooling for TB diagnosis; these developments are primarily respiratory and should not be extrapolated to genital specimens without validation. Conclusion: ** Genital tuberculosis should be diagnosed through an integrated, specimen-aware pathway rather than a single-test paradigm. The major research priorities are standardized genital specimen collection, multicentre diagnostic-accuracy studies using carefully designed composite reference standards, direct comparison of modern rapid NAATs, validation of non-invasive specimens such as menstrual blood, and genital-TB-specific evaluation of targeted sequencing and other emerging molecular technologies.
Zitieren
APA
Nandagopal, M., & K, G. (2026). Genital Tuberculosis in the Molecular Era Conventional Diagnosis, Molecular Testing, Specimen Selection and Emerging Genomic Technologies: A Critical Review. Journal of Infectious Diseases & Travel Medicine, 10(2), 1-16. https://doi.org/10.23880/jidtm-16000206
Vancouver
Nandagopal M, K G. Genital Tuberculosis in the Molecular Era Conventional Diagnosis, Molecular Testing, Specimen Selection and Emerging Genomic Technologies: A Critical Review. Journal of Infectious Diseases & Travel Medicine. 2026;10(2):1-16. doi:10.23880/jidtm-16000206
BibTeX
@article{Nandagopal2026,
author = {Nandagopal, Murugan and K, Gohilavarshini},
title = {Genital Tuberculosis in the Molecular Era Conventional Diagnosis, Molecular Testing, Specimen Selection and Emerging Genomic Technologies: A Critical Review},
journal = {Journal of Infectious Diseases & Travel Medicine},
year = {2026},
volume = {10},
number = {2},
pages = {1--16},
doi = {10.23880/jidtm-16000206}
}
EUVIMED